Journal · Oncology · Updated 21 November 2026
Current Treatment Options in Oncology
Read Current Treatment Options in Oncology articles on DeepDyve. No university library needed.
Current Treatment Options in Oncology has published since 2000 and offers reviews and expert opinion on cancer treatment, from breast cancer and melanoma to CAR-T cell therapy, radionuclide therapy and cancer pain. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Current Treatment Options in Oncology at a glance
- Full title
- Current Treatment Options in Oncology
- Abbreviation (NLM)
- Curr Treat Options Oncol
- Publisher
- Springer Nature
- Print ISSN
- 1527-2729
- Online ISSN (eISSN)
- 1534-6277
- First published
- 2000
- Subjects
- Neoplasms
- Access model
- Hybrid (34% free to read in 2026)
Ways to access Current Treatment Options in Oncology
34% of the articles Current Treatment Options in Oncology published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 34% of Current Treatment Options in Oncology articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Current Treatment Options in Oncology. Check its journal list and whether it offers remote access.
- DeepDyve. Read Current Treatment Options in Oncology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Current Treatment Options in Oncology’s 2025 Journal Impact Factor is 5.8, and its 5-year Impact Factor is 5.1.
5.8
Journal Impact Factor (2025)
5.1
5-year Impact Factor (2025)
4 days
Median time to first decision
Source: journal metrics on the Current Treatment Options in Oncology homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Current Treatment Options in Oncology research worth reading
Published January to April 2026. Summaries describe what the authors report.
-
Systemic Therapy for Salivary Gland Cancers: A Review of Targeted and Chemotherapeutic Approaches
Hintze and colleagues review systemic therapy for recurrent and metastatic salivary gland cancers, noting that androgen receptor blockade and HER2-directed therapy in biomarker-selected tumors have shown superior response rates compared with the single digit rates of unselected chemotherapy or tyrosine kinase inhibitors.
Hintze et al. · Current Treatment Options in Oncology, published online January 19, 2026 · DOI 10.1007/s11864-026-01380-6
-
Research Priorities and Future Directions in Cardio-Oncology
Mszar and colleagues outline evidence gaps in cardio-oncology, from risk estimation and clinical trials to rehabilitation, health equity and machine learning, as the number of cancer survivors is projected to exceed 26 million by 2040.
Mszar et al. · Current Treatment Options in Oncology, published online January 4, 2026 · DOI 10.1007/s11864-025-01366-w
-
Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer
The authors argue for biomarker-driven second-line treatment of HR+ metastatic breast cancer after CDK4/6 inhibitors, favoring oral SERDs for ESR1-mutated tumors, fulvestrant with capivasertib for PIK3CA–AKT–PTEN alterations, and antibody–drug conjugates for rapid progression.
Cetin et al. · Current Treatment Options in Oncology, published online April 18, 2026 · DOI 10.1007/s11864-026-01391-3
-
Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia
Peters and colleagues review menin inhibitors in acute myeloid leukemia with KMT2A rearrangements or NPM1 mutations, including the FDA approvals of revumenib and ziftomenib, and note resistance mechanisms identified through mutations of the MEN1 gene.
Peters et al. · Current Treatment Options in Oncology, published online March 17, 2026 · DOI 10.1007/s11864-025-01378-6
-
Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review
In a narrative review, Wang and colleagues describe cancer pain management moving toward a personalized, multimodal approach, and report that emerging options such as cannabinoids, anti-NGF antibodies and TRPV1-targeted therapies show variable efficacy and need further evaluation before routine use.
Wang et al. · Current Treatment Options in Oncology, published online April 24, 2026 · DOI 10.1007/s11864-026-01393-1
See every Current Treatment Options in Oncology article on DeepDyve
Related journals
Questions about Current Treatment Options in Oncology
How can I read Current Treatment Options in Oncology articles without a subscription?
34% of Current Treatment Options in Oncology articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Treatment Options in Oncology articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Current Treatment Options in Oncology?
Current Treatment Options in Oncology’s NLM (PubMed) abbreviation is Curr Treat Options Oncol.
What is the ISSN of Current Treatment Options in Oncology?
The print ISSN is 1527-2729 and the online ISSN is 1534-6277.
What is the impact factor of Current Treatment Options in Oncology?
Current Treatment Options in Oncology’s Journal Impact Factor is 5.8 (2025), and its 5-year Impact Factor is 5.1, according to Springer Nature’s published metrics.
Is Current Treatment Options in Oncology open access?
Current Treatment Options in Oncology is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 19 of 56 Current Treatment Options in Oncology articles (34%) carry a Creative Commons license, per Crossref.
Current Treatment Options in Oncology articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.
Start reading Current Treatment Options in Oncology today
One month free, then less than $2 a day. Current Treatment Options in Oncology, plus millions of articles from thousands of journals.





